Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2004-10-15
2009-11-24
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S184100
Reexamination Certificate
active
07622107
ABSTRACT:
Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic.
REFERENCES:
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5583038 (1996-12-01), Stover
patent: 5591632 (1997-01-01), O'Donnell et al.
patent: 5679515 (1997-10-01), Stover et al.
patent: 5700683 (1997-12-01), Stover et al.
patent: 5736367 (1998-04-01), Haun et al.
patent: 5776465 (1998-07-01), O'Donnell et al.
patent: 5807723 (1998-09-01), Aldovini et al.
patent: 5830475 (1998-11-01), Aldovini et al.
patent: 5854055 (1998-12-01), Bloom et al.
patent: 5866403 (1999-02-01), Aldovini et al.
patent: 5869057 (1999-02-01), Rock
patent: 6015696 (2000-01-01), Yamada et al.
patent: 6471967 (2002-10-01), Horwitz et al.
patent: 7288261 (2007-10-01), Orme et al.
patent: 88/06626 (1988-09-01), None
patent: 2004/031356 (2004-04-01), None
Cirillo et al., “Bacterial Vaccine Vectors and Bacillus Calmette-Guerin”, Clinical Infectious Diseases, 20:1001-9 (1995).
Fuerst et al., “Development and Analysis of Recombinant BCG Vector Systems”, AIDS Research and Human Retroviruses, 8:1451-5 (1992).
Hanson et al., “Efficacy and Safety of Live Recombinant BCG Vaccines”, Dev. Biol. Stand., 84:229-36 (1995).
Harth et al., “High-Level Heterologous Expression and Secretion in Rapidly Growing Nonpathogenic Mycobacteria of Four MajorMycobacterium tuberculosisExtracellular Proteins Considered to be Leading Vaccine Candidates and Drug Targets”, Infection and Immunity, 65:2321-8 (1997).
Harth et al., “Novel Insights into the Genetics, Biochemistry, and Immunocytochemistry of the 30-Kilodalton Major Extracellular Protein ofMycobacterium tuberculosis”, Infection and Immunity, 64:3038-47 (1996).
Horwtiz et al., “RecombinantBacillus calmette-guerin(BCG) Vaccines Expressing theMycobacterium tuberculosis30-kDa Major Secretory Protein Induce Greater Protective Immunity Against Tuberculosis Than Conventional BCG Vaccines in a Highly Susceptible Animal Model”, PNAS, 97:13853-8 (2000).
Langermann et al., “Protective Humoral Response Against Pneumococcal Infection in Mice Elicited by Recombinant Bacille Calmette-Guerin Vaccines Expressing Pneumococcal Surface Protein A”, J Exp Med., 180:2277-86 (1994).
Langermann et al., “Systemic and Mucosal Immunity Induced by BCG Vector Expressing Outer-Surface Protein A of Borrelia Burgdorferi”, Nature, 372:552-5 (1994).
Lee et al., “T-Cell Epitope Mapping of the Three Most Abundant Extracellular Proteins ofMycobacterium tuberculosisin Outbred Guinea Pigs”, Infection and Immunity, 67:2665-70 (1999).
Naito et al., “The Antigen 85 Complex Vaccine Against ExperimentalMycobacterium lepraeInfection in Mice”, Vaccine, 19:795-8 (2000).
Ohara et al., “Characterization of the Transcriptional Initiation Regions of Genes for the Major Secreted Protein Antigens 85C and MPB51 ofMycobacerium bovisBCG”, Microbial Pathogenesis, 23:303-10, (1997).
Ohara et al., “Inhibition of Multiplication ofMycobacterium lepraein Mouse Foot Pads by RecombinantBacillus calmette-guerin(BCG)”, Vaccine, 19:1294-7 (2000).
Stover et al., “New Use of BCG for Recombinant Vaccines”, Nature, 351:456-60 (1991).
Stover et al., “Protective Immunity Elicited by rBCG Vaccines”, Dev. Biol. Stand., 82:163-70 (1994).
Stover et al., “Protective Immunity Elicited by Recombinant Bacille Calmette-Guerin (BCG) Expressing Outer Surface Protein A (OspA) Lipoprotein: A Candidate Lyme Disease Vaccine”, J. Exp. Med., 178:197-209 (1993).
Stover et al., “Use of Recombinant BCG as a Vaccine Delivery Vehicle”, Advances in Experimental Medicine and Biology, 327: 175-82 (1992).
Yasutomi et al., “Immunization with Recombinant BCG-SIV Elicits SIV-Specific Cytotoxic T. Lymphocytes in Rhesus Monkeys”, The Journal of Immunology, 150:3101-7 (1993).
Brooks JV et al. “Boosting vaccine for tuberculosis.” Infect. Immun. 69:2714-17, 2001.
Belisle, JT et al. “Role of the major antigen ofMycobacterium tuberculosisin cell wall biogenesis.” Science 276:1420-1422, 1997.
Horwitz, MA et al. “Protective immunity against tuberculosis induced by vaccination with major extracellular proteins ofMycobacterium tuberculosis.” Proc. Natl. Acad. Sci. USA 92:1530-1534, 1995.
Harth Gunter
Horwitz Marcus A.
Cullman, Esq. Louis C.
Glasky Michelle S.
K&L Gates LLP
Navarro Mark
The Regents of the University of California
LandOfFree
Recombinant intracellular pathogen immunogenic compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant intracellular pathogen immunogenic compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant intracellular pathogen immunogenic compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058513